English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Cancer with more than 11 million deaths per year is the second principal cause of death. It is estimated that there will be 16 million new cases every year by 2020. Deaths from cancer are predicted to be rising, with an expected 9 million people dying from cancer in 2015 and 11.4 million dying in 2030, worldwide. Additionally, gastric cancer is the second most common form of cancer-related deaths, globally. Cancer immunotherapy has been introduced as an influential and promising clinical trend for the treatment of cancer and it has been successful in treatment of breast and prostate cancers as well as melanoma [1]. Tumors are appeared by the progressive growth and proliferation of non-programmed cells. It is probable that cancerous cells occur daily in healthy individuals; however in the majority of cases, they are detached by the immune system and cannot grow into malignancies. The above-mentioned capability of the immune system to sense and eliminate cancerous cells is known as “immune surveillance”. Cancerous cells are detected by innate and adaptive immune cells which sense the local environment of a malignancy when it begins to remodel the stroma [1]. The crucial aim of immunotherapy is overcoming malignancies by inducing an efficient immune response against the cancerous cells. In theory, if particular antigens could be recognized in the forerunner lesions leading to a tumor, the immune responses can be used to eradicate them which may prevent the cancerous cells to convert into a malignancy [2]. Gastric cancer is potentially a suitable target for such defensive immunotherapy as it progresses over an extended period of time and its premalignant lesions are clearly identifiable which if effectively targeted, their development to forthright tumor could be prevented. Current immune therapies of gastric tumors are frequently based on utilizing monoclonal antibodies (vaccine and drugs), cytotoxic immunocytes, or gene transferred vaccines [3]. Experimental vaccination methodologies involve using whole protein and peptide vaccines, based on recognition of certain peptides by cytotoxic ABSTRACT Introduction: Gastric cancer, as the second reason of cancer mortality around the world, is defined as one of the serious health problems and a wide range of current research is focused to overcome the challenges relevant to its successful therapy. Employing recent approaches in the field of vaccine tumor therapy and immunotherapic strategies such as utilization of monoclonal antibodies can play significant roles in achieving efficient therapeutic means to combat the disease. Methods: In this study, computational methods including three-dimensional modeling, based on sequence combinational pattern identification together with docking procedures have been employed for design and in silico construction of prolific and effective antibody structures against HER-2 and MAGE-3 antigens. Results: These methods led to introduction of novel and efficient anti-HER2 and anti-MAGE3 antibodies. For instance, combinational pattern of bH1 antibody (light chain) and IGG1-KAPPA 4D5 antibody (heavy chain) which obtained an exceptional score of 844.83 KJ/mol as the new candidate for cancer vaccine therapy, whereas Herceptin scored 453.4 KJ/mol. In addition, the suggested pattern for designing antibody against MAGE-3 with combination of bH1 antibody (heavy chain) and HLA-A 0201 (light chain) achieved acceptable score of 640.8 KJ/mol. Conclusion: It is envisaged that the results obtained from the current research could be utilized to develop efficient combined strategies for vaccine therapy of gastric cancer.

vaccine research

Design and in Silico Construction of New Efficient Antibodies Against Gastric Tumor-associated Antigens Towards Introducing Combined Strategy for Vaccine Tumor Therapy